Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$22.03
+0.0%
$24.32
$19.11
$48.45
$2.06B0.193,183 shs537 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$56.24
+2.9%
$53.86
$18.89
$60.08
$2.28B0.61272,884 shs185,402 shs
Prothena Corporation plc stock logo
PRTA
Prothena
$11.19
+3.7%
$9.80
$4.32
$11.69
$602.36M-0.23490,086 shs306,797 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$21.79
-1.1%
$19.58
$10.41
$63.92
$2.30B0.262.86 million shs2.19 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.00%-0.13%-14.85%+0.04%-8.40%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-2.23%-1.13%+32.87%+181.78%
Prothena Corporation plc stock logo
PRTA
Prothena
0.00%-1.39%+7.91%+21.18%+25.18%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+2.43%-7.49%+5.97%-66.16%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$22.03
+0.0%
$24.32
$19.11
$48.45
$2.06B0.193,183 shs537 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$56.24
+2.9%
$53.86
$18.89
$60.08
$2.28B0.61272,884 shs185,402 shs
Prothena Corporation plc stock logo
PRTA
Prothena
$11.19
+3.7%
$9.80
$4.32
$11.69
$602.36M-0.23490,086 shs306,797 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$21.79
-1.1%
$19.58
$10.41
$63.92
$2.30B0.262.86 million shs2.19 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.00%-0.13%-14.85%+0.04%-8.40%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-2.23%-1.13%+32.87%+181.78%
Prothena Corporation plc stock logo
PRTA
Prothena
0.00%-1.39%+7.91%+21.18%+25.18%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+2.43%-7.49%+5.97%-66.16%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.25
Buy$46.67111.83% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.43
Hold$42.40-24.61% Downside
Prothena Corporation plc stock logo
PRTA
Prothena
2.36
Hold$21.6793.63% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.11
Hold$32.6349.75% Upside

Current Analyst Ratings Breakdown

Latest PRTA, SRPT, PAHC, and AAPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/27/2026
Prothena Corporation plc stock logo
PRTA
Prothena
DowngradeSell (D-)Sell (E+)
4/24/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Initiated CoverageBuy$40.00
4/22/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (D-)Sell (D)
4/16/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Reiterated RatingSell
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageNeutral$62.00
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageHold$62.00
4/13/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Reiterated RatingBuy$48.00
4/7/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetSector Perform$18.00 ➝ $19.00
4/6/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
UpgradeStrong-Buy
3/26/2026
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
Reiterated RatingBuy$48.00
3/26/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetOutperform$29.00 ➝ $35.00
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$82.10M25.04N/AN/A$2.04 per share10.80
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.46B1.56$3.35 per share16.79$7.05 per share7.98
Prothena Corporation plc stock logo
PRTA
Prothena
$9.68M62.23N/AN/A$5.21 per share2.15
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B1.05N/AN/A$10.89 per share2.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$177.71MN/AN/AN/AN/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.2525.0017.150.846.29%38.28%8.37%5/6/2026 (Estimated)
Prothena Corporation plc stock logo
PRTA
Prothena
-$244.09M-$4.54N/AN/A0.37-2,520.57%-65.89%-56.00%5/7/2026 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$8.44N/A10.790.33-38.34%-50.74%-18.00%5/6/2026 (Estimated)

Latest PRTA, SRPT, PAHC, and AAPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.31N/AN/AN/A$0.81 millionN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72N/AN/AN/A$367.02 millionN/A
5/6/2026Q1 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.9760N/AN/AN/A$474.16 millionN/A
3/25/2026Q4 2025
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A-$0.5150N/A-$0.5150N/A$24.72 million
2/25/2026Q4 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 million
2/19/2026Q4 2025
Prothena Corporation plc stock logo
PRTA
Prothena
-$0.45-$0.44+$0.01-$0.40$0.67 million$0.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.480.85%N/A21.33%N/A
Prothena Corporation plc stock logo
PRTA
Prothena
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
0.57
1.79
1.77
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.14
3.05
1.22
Prothena Corporation plc stock logo
PRTA
Prothena
N/A
7.72
7.72
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.73
2.32
1.48

Institutional Ownership

CompanyInstitutional Ownership
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Prothena Corporation plc stock logo
PRTA
Prothena
97.08%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
60093.33 millionN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.54 million20.22 millionOptionable
Prothena Corporation plc stock logo
PRTA
Prothena
13053.83 million48.23 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,372105.57 million98.29 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$22.03 +0.01 (+0.05%)
Closing price 03:59 PM Eastern
Extended Trading
$22.08 +0.05 (+0.23%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$56.24 +1.56 (+2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$56.33 +0.09 (+0.16%)
As of 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Prothena stock logo

Prothena NASDAQ:PRTA

$11.19 +0.40 (+3.71%)
Closing price 04:00 PM Eastern
Extended Trading
$11.18 -0.01 (-0.09%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$21.79 -0.25 (-1.13%)
Closing price 04:00 PM Eastern
Extended Trading
$21.90 +0.11 (+0.50%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.